title: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.
abstract: OBJECTIVE
  To evaluate the activity and the toxicity of the combination of cisplatin (CDDP)/recombinant interleukin-2 (rIL-2) and interferon alfa-2a (IFN alpha) in disseminated malignant melanoma (DMM).
  
  
  METHODS
  Between December 1990 and March 1992, 39 patients with biopsy-proven metastatic malignant melanoma (MM), bidimensionally measurable lesions and an Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 entered this protocol. Seventy-nine percent had received previous chemotherapy including platinum complex (15%) and alpha interferon (44%). They received CDDP (100 mg/m2 on day 0) followed by IL-2 18.10(6) IU/m2/d continuous intravenous (IV) infusion from day 3 to day 6 and from day 17 to day 21. The cycle was repeated on day 28. Subcutaneous IFN alpha 9.10(6) IU three times weekly was administered throughout the treatment period. From day 66 or 94, patients were administered a maintenance cycle with CDDP 100 mg/m2, subcutaneous IL-2 5.10(6) IU/m2/d from day 15 to day 19 and from day 22 to day 26 and IFN alpha 9.10(6) IU three times weekly repeated every 5 weeks (maximum four cycles).
  
  
  RESULTS
  Among 39 assessable patients, five patients achieved complete responses (CRs). Sixteen patients had partial responses (PRs). The overall objective response rate was 53.8%. The number of metastatic sites was the only response-predictive factor. Toxicity was manageable in a routine patient setting and there was no life-threatening toxicity.
  
  
  CONCLUSIONS
  These results seem to indicate a possible synergy between CDDP/rIL-2 and IFN alpha in MM.
authors.affiliation: Service d'Oncologie Médicale, Hopital de la Salpétrière, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Khayat
authors.forename: C
authors.initials: C
authors.lastname: Borel
authors.forename: J M
authors.initials: JM
authors.lastname: Tourani
authors.forename: A
authors.initials: A
authors.lastname: Benhammouda
authors.forename: E
authors.initials: E
authors.lastname: Antoine
authors.forename: O
authors.initials: O
authors.lastname: Rixe
authors.forename: E
authors.initials: E
authors.lastname: Vuillemin
authors.forename: P A
authors.initials: PA
authors.lastname: Bazex
authors.forename: L
authors.initials: L
authors.lastname: Thill
authors.forename: R
authors.initials: R
authors.lastname: Franks
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D002945:Cisplatin